Molecular Templates, Inc. MTEM
We take great care to ensure that the data presented and summarized in this overview for Molecular Templates, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in MTEM
Top Purchases
Top Sells
About MTEM
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT-5111, an ETB candidate that is in Phase I clinical trial for the treatment of HER2-positive cancers; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory myeloma patients; and MT-6402 in that is in Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients. Its pipeline of ETBs in development for other targets, including CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.
Insider Transactions at MTEM
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 14
2024
|
Target N V Biotech |
SELL
Open market or private sale
|
Direct |
1,279,820
-100.0%
|
$0
$0.66 P/Share
|
|
Apr 02
2024
|
Target N V Biotech |
BUY
Open market or private purchase
|
Direct |
250,000
+16.34%
|
$500,000
$2.35 P/Share
|
|
Apr 02
2024
|
Kevin M. Lalande |
BUY
Grant, award, or other acquisition
|
Indirect |
175,000
+50.0%
|
$350,000
$2.35 P/Share
|
|
Jul 17
2023
|
Target N V Biotech |
BUY
Open market or private purchase
|
Direct |
4,255,319
+21.6%
|
$0
$0.47 P/Share
|
|
Jul 07
2022
|
Jason S. Kim Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,089
+11.24%
|
$0
$0.71 P/Share
|
|
Jun 16
2022
|
Sean Mc Lennan Officer |
BUY
Open market or private purchase
|
Direct |
30,000
+50.0%
|
$0
$0.82 P/Share
|
|
Jun 15
2022
|
Shv Management Services, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
62,000
+21.83%
|
$0
$0.89 P/Share
|
|
Jun 15
2022
|
Kevin M. Lalande |
BUY
Open market or private purchase
|
Indirect |
62,000
+21.83%
|
$0
$0.89 P/Share
|
|
Jun 14
2022
|
Shv Management Services, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
60,000
+27.27%
|
$0
$0.87 P/Share
|
|
Jun 14
2022
|
Kevin M. Lalande |
BUY
Open market or private purchase
|
Indirect |
60,000
+27.27%
|
$0
$0.87 P/Share
|
|
Jun 13
2022
|
Shv Management Services, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
100,000
+50.0%
|
$0
$0.91 P/Share
|
|
Jun 13
2022
|
Kevin M. Lalande |
BUY
Open market or private purchase
|
Indirect |
100,000
+50.0%
|
$0
$0.91 P/Share
|
|
May 16
2022
|
Target N V Biotech |
BUY
Open market or private purchase
|
Direct |
200,000
+1.76%
|
$200,000
$1.18 P/Share
|
|
Apr 27
2022
|
Eric E Poma |
BUY
Exercise of conversion of derivative security
|
Direct |
34,156
+5.81%
|
$0
$0.71 P/Share
|
|
Jan 06
2022
|
Target N V Biotech |
BUY
Open market or private purchase
|
Direct |
200,000
+1.79%
|
$800,000
$4.04 P/Share
|
|
Sep 21
2021
|
Target N V Biotech |
BUY
Open market or private purchase
|
Direct |
750,000
+6.5%
|
$4,500,000
$6.0 P/Share
|
|
Sep 16
2021
|
Target N V Biotech |
BUY
Open market or private purchase
|
Direct |
100,000
+0.99%
|
$600,000
$6.13 P/Share
|
|
Jul 27
2021
|
Target N V Biotech |
BUY
Open market or private purchase
|
Direct |
75,000
+0.75%
|
$525,000
$7.09 P/Share
|
|
Jul 26
2021
|
Target N V Biotech |
BUY
Open market or private purchase
|
Direct |
80,000
+0.8%
|
$560,000
$7.0 P/Share
|
|
Jul 20
2021
|
Target N V Biotech |
BUY
Open market or private purchase
|
Direct |
125,000
+1.26%
|
$875,000
$7.13 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 250K shares |
|---|---|
| Grant, award, or other acquisition | 175K shares |
| Open market or private sale | 1.28M shares |
|---|